Boston Scientific today launched the LUX-Dx II+ insertable cardiac monitor (ICM) system, describing it as a next-generation insertable monitor for long-term monitoring of arrhythmias associated with conditions such as atrial fibrillation (AF), cryptogenic stroke and syncope.
The system is designed with dual-stage algorithms that detect and then verify potential arrhythmias before an alert is sent to clinicians, thereby providing actionable data for clinical decision-making, Boston Scientific said in a statement. Further, the remote programming capabilities of the device allow physicians and care teams to adjust event detection settings and record symptoms without requiring an in-person patient appointment.
The dual-stage algorithms within the LUX-Dx II+ ICM system can be programmed to identify AF, atrial and ventricular tachycardia, bradycardia and rhythm pause episodes. These algorithms, including a new premature ventricular contraction (PVC) burden, allow the device to detect arrhythmias each time established thresholds or parameters are exceeded.
Additional levels of verification filters are then applied, including additional options for nighttime programming specific to bradycardia and pause episodes, which were developed to reject false positive detections and irrelevant episodes. Patients will also have a new downloadable app option for more convenient and seamless remote monitoring.
“The LUX-Dx II+ ICM system builds on a strong foundation of cardiac diagnostic technologies at Boston Scientific to provide care teams with the necessary data for critical decision making,” said Scott Olson, senior vice president and president, Cardiac Rhythm Management and Diagnostics, Boston Scientific. “With enhanced and new diagnostic algorithms, physicians will receive timely, accurate and actionable insights to help them make clinically meaningful decisions